In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Sensus Healthcare (SRTS – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $7.04.
Vendetti covers the Healthcare sector, focusing on stocks such as PAVmed, Dermata Therapeutics, and Icecure Medical. According to TipRanks, Vendetti has an average return of 1.1% and a 33.53% success rate on recommended stocks.
Sensus Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $16.00, which is a 127.27% upside from current levels. In a report released yesterday, Alliance Global Partners also maintained a Buy rating on the stock with a $14.50 price target.
See today’s best-performing stocks on TipRanks >>
SRTS market cap is currently $116.9M and has a P/E ratio of 4.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
Read More on SRTS:
- Sensus Healthcare reports Q4 EPS 17c, consensus 23c
- Sensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million
- Sensus Healthcare to Host Fourth Quarter 2022 Financial Results and Business Update Conference Call on February 9, 2023
- Sensus Healthcare announces senior managment appointments
- Sensus Healthcare Announces Preliminary Fourth Quarter 2022 Revenues
